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Frontostriatal grey matter atrophy  
in amyotrophic lateral sclerosis
A visual rating study
Ratko Radakovic1,2,4, Vaisakh Puthusseryppady1, Emma Flanagan1,  
Matthew C. Kiernan3, Eneida Mioshi1, Michael Hornberger1
ABSTRACT. Amyotrophic lateral sclerosis (ALS) is characterised by frontostriatal grey matter changes similar to those 
in frontotemporal dementia (FTD). However, these changes are usually detected at a group level, and simple visual 
magnetic resonance imaging (MRI) cortical atrophy scales may further elucidate frontostriatal changes in ALS. Objective: 
To investigate whether frontostriatal changes are detectable using simple visual MRI atrophy rating scales applied at an 
individual patient level in ALS. Methods: 21 ALS patients and 17 controls were recruited and underwent an MRI scan. 
Prefrontal cortex sub-regions of the medial orbitofrontal cortex (MOFC), lateral orbitofrontal cortex (LOFC) and anterior 
cingulate cortex (ACC), striatal sub-regions of the caudate nucleus (CN) and nucleus accumbens (NAcc) were rated 
using visual grey matter atrophy 5-point Likert scales. Results: Significantly higher atrophy ratings in the bilateral MOFC 
only in ALS patients versus controls was observed (p<.05). Patients with greater MOFC atrophy had significantly higher 
atrophy of the CN (p<.05) and LOFC (p<.05). Conclusion: Use of simple visual atrophy rating scales on an individual 
level reliably detects frontostriatal deficits specific to ALS, showing MOFC atrophy differences with associated CN and 
LOFC atrophy. This is an applicable method that could be used to support clinical diagnosis and management. 
Key words: amyotrophic lateral sclerosis, magnetic resonance imaging, orbitofrontal cortex, striatum, visual atrophy 
rating scale.
ATROFIA DA MASSA CINZENTA FRONTOSTRIATAL NA ESCLEROSE LATERAL AMIOTRÓFICA: UM ESTUDO DE AVALIAÇÃO 
VISUAL ANTES DA PUBLICAÇÃO
RESUMO. A esclerose lateral amiotrófica (ELA) é caracterizada por alterações na substância cinzenta frontostriatal, 
semelhantes às da demência frontotemporal (DFT). No entanto, essas alterações geralmente são detectadas em nível 
de grupo, e as escalas simples de atrofia cortical por ressonância magnética visual (MRI) podem elucidar ainda mais as 
alterações frontostriatais na ELA. Objetivo: Investigar se as alterações frontostriatais são detectáveis  usando escalas 
de classificação de atrofia MRI visuais simples aplicadas em um nível de paciente individual em ELA. Métodos: 21 
pacientes com ELA e 17 controles foram recrutados e submetidos a uma ressonância magnética. Sub-regiões do córtex 
pré-frontal do córtex orbitofrontal medial (MOFC), córtex orbitofrontal lateral (LOFC) e córtex cingulado anterior (ACC), 
sub-regiões estriadas do núcleo caudado (NC) e nucleus accumbens (NAcc) foram classificadas usando escalas de 
atrofia de substância cinzenta visuais de Likert de 5 pontos. Resultados: Observações de atrofia significativamente 
maiores no MOFC bilateral em pacientes com ELA versus controles foram observadas apenas (p <0,05). Pacientes com 
maior atrofia do MOFC tiveram atrofia significativamente maior do CN (p <0,05) e LOFC (p <0,05). Conclusão: O uso de 
escalas de avaliação de atrofia visuais simples em um nível individual detecta de forma confiável déficits frontostriatais 
específicos para ELA, mostrando diferenças de atrofia MOFC com atrofia associada de CN e LOFC. Este é um método 
aplicável que pode ser usado para apoiar o diagnóstico e o gerenciamento clínico.
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Subcortical atrophy still remains largely clinically undetected in amyotrophic lateral sclerosis (ALS), 
despite recent evidence showing significant atrophy in 
subcortical regions.1,2 Subcortical changes should not be 
surprising in ALS, as frontotemporal dementia (FTD), 
which lies on a disease spectrum with ALS,3,4 also exhib-
its significant subcortical, and particularly frontostriatal 
atrophy in the early stages.5 The medial prefrontal cortex 
regions are strongly connected to striatal regions and 
previous research has shown that both have been asso-
ciated with cognitive functioning and behaviour, which 
are often affected in FTD and ALS.6 
However, detection of this frontostriatal atrophy 
clinically remains limited, as such changes have only 
been investigated at a group level7 and with imaging 
techniques that are difficult to be utilised clinically (e.g. 
voxel-based morphometry, cortical thickness). By con-
trast, visual magnetic resonance imaging (MRI) atrophy 
rating scales8 are reliable tools used in clinical practice 
for detection of atrophy at an individual patient level. 
Previous research using MRI rating scales has shown 
greater atrophy in the medial prefrontal cortex and 
orbitofrontal cortex in behavioural variant FTD (bvFTD) 
patients compared to Alzheimer’s Disease patients and 
controls.9,10 Further, in terms of the ALS-FTD spectrum, 
visual atrophy ratings showed that patients with ALS-
FTD and bvFTD had higher orbitofrontal cortex, ante-
rior cingulate cortex, motor cortex and anterior tempo-
ral lobe atrophy compared to controls.10 Notably, in this 
same study, patients with ALS only significantly differed 
to controls for the orbitofrontal cortex.
Therefore, we selected areas of the prefrontal cor-
tex driven by previous research on the ALS-FTD spec-
trum,9,11 specifically the orbitofrontal cortex (medial and 
lateral subdivisions) and the anterior cingulate cortex. 
Further striatal areas were chosen based on previous 
research,1,5 specifically the caudate nucleus and nucleus 
accumbens. The current study aimed to investigate 
whether a clinically feasible visual MRI atrophy rating 
scale could be employed to reliably detect frontostriatal 
changes in ALS. 
METHODS
Case selection
A total of 21 ALS patients without dementia were 
recruited from the Sydney ALS clinic, all fulfilling 
diagnostic criteria for ALS12 and ALS-FTD.3 Seventeen 
controls were also recruited from a healthy control 
panel. All participants underwent an MRI scan. Further, 
patients were rated on the ALS-Functional Rating Scale-
Revised13 and Addenbrooke’s Cognitive Examination-
Revised (ACE-R),14 and Cambridge Behavioural Inven-
tory-Revised (CBI-R)15 scores were available. CBI-R 
scores were converted to percentages, as in previous 
research.16 
Ethics approval for the study was obtained from the 
Human Research Ethics Committee of the South Eastern 
Sydney/Illawarra Area Health Service (HREC10/126). 
Consent was obtained from all participants following 
the ethos of the Declaration of Helsinki.
Image acquisition and scan rating
All patients and controls underwent the same imaging 
protocol with whole-brain T1-weighted images using a 
3-Tesla Philips MRI scanner with standard quadrature 
head coil (coronal orientation, matrix 256×256, 200 
slices, 1×1 mm2 in-plane resolution, slice thickness 1 
mm, TE/TR=2.6/5.8 ms, flip angle α=19°).
Two trained raters (RR and VP), blind to diagnosis, 
rated axial and coronal T1 MRIs on a 5-point Likert 
scale, with 0 indicating normal and 4 indicating severe 
atrophy using methodology described previously.8,11 We 
selected the medial orbitofrontal cortex (MOFC), lateral 
orbitofrontal cortex (LOFC) and the anterior cingulate 
cortex (ACC) as prefrontal cortex regions of interest. The 
boundary between MOFC and LOFC was differentiated 
using the crown of the gyrus rectus.17 In terms of the 
striatum, we selected the caudate nucleus (CN) and the 
nucleus accumbens (NAcc), which was identified using 
the rostrum of the corpus callosum as a marker. Based 
on prefrontal cortex and CN rating methods, we devel-
oped a visual rating for the NAcc (See Supplementary 
Figure 1 – available on the site www.demneuropsy.com.
br/). Left and right regions were rated independently. 
For all of the scales, both raters showed excellent intra-
rater reliability (RR Cronbach Standardised Alpha=0.93; 
VP Cronbach Alpha=0.92) and very good inter-rater reli-
ability (Kappa=0.81, p<.001) on an independent MRI 
atrophy rating training set of 38 scans.
Statistical analysis
Data was analysed using R statistical software. Shapiro-
Wilk tests were used to examine normality of data. 
Parametric statistics (t test) were used to examine 
demographic variables, while the Chi squared test was 
used to compare gender distribution between patients 
and controls. Total brain atrophy was derived by adding 
the atrophy ratings of the MOFC, LOFC, ACC, CN and 
NAcc. Total prefrontal atrophy was derived by adding 
the atrophy ratings of the MOFC, LOFC and ACC, 
whereas total striatal atrophy was derived by adding 
atrophy of the CN and NAcc. Within-region visual 
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atrophy rating differences and laterality were examined 
using Bonferroni-corrected Mann-Whitney U and the 
left-right average was taken for further comparison 
based on previous research.11 Spearman’s Rho was used 
for correlational comparisons.
RESULTS
Demographic and background comparison
There was no significant age or education difference 
between ALS patients and controls (Table 1). Patient 
and control groups differed in gender distribution. 
Scan ratings
On this set of MRI scans, for all scales both raters 
showed excellent intra-rater reliability (RR Cronbach 
Standardised Alpha=0.95; VP Cronbach Alpha=0.94) 
and very good inter-rater reliability (Kappa=0.81, 
p<.001). Within-patient group gender comparison 
and within-control group gender comparison showed 
no significant difference between males and females 
in grey matter atrophy for the prefrontal cortex and 
striatum.
Overall, there was no significant difference in total 
brain atrophy, total prefrontal cortex and total striatum 
atrophy ratings, between patients and controls. On lat-
eralization analysis, there were no significant differ-
ences in atrophy between left and right MOFC, LOFC, 
ACC, CN or NAcc. Subdivision of the prefrontal cortex 
showed significantly higher atrophy rating in MOFC in 
ALS patients versus controls (see Table 2). No significant 
Table 1. Demographics of ALS patients and controls.
ALS (N=21) Controls (N=17) Test statistic p value
Age (Mean, SD) 61.8 (13.1) 54.5 (14.3) t=1.65 NS
Years of Education (Mean, (SD) 12.7 (3.6) 13.4 (1.8)† t=0.26 NS
Gender (M/F) 10/11 2/15 χ2=5.59 < .05
Age at onset (Mean, SD) 59.0 (12.9)
Disease duration, years (Mean, SD) 2.2 (2.1)
Site of Onset (Bulbar/Limb) 7/14
ALSFRS-R Total (Mean, SD) /48 38.7 (7.4)
Bulbar subscore (Mean, SD) /12 8.6 (3.0)
Fine motor subscore (Mean, SD) /12 9.0 (3.0)
Gross motor subscore (Mean, SD) /12 9.7 (3.2)
Respiratory subscore (Mean, SD) /12 11.4 (0.8)
ACE-R (Mean, SD)/100 90 (9.0)
CBI-R (Mean, SD) % deficit 14.6 (11.4)
† N: 9; SD: Standard Deviation; ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; ACE-R: Addenbrooke’s Cognitive Examination-Revised; CBI-R: Cambridge Behaviour 
Inventory-Revised. Note: Age and Years of Education were normally distributed according to Shapiro Wilk tests (p > .05)
Table 2. Scan Rating comparison (mean and standard deviation) between ALS and control groups
ALS Controls Test statistic p value
ACC 1.5 (0.7) 0.9 (0.6) U=236.0 NS
LOFC 1.2 (0.7) 0.9 (0.7) U=221.0 NS
MOFC 1.1 (0.6) 0.5 (0.5) U=263.0 < .05
CN 1.4 (1.1) 0.8 (0.8) U=217.5 NS
NAcc 1.6 (1.1) 0.7 (0.8) U=188.5
NS ACC: Anterior Cingulate Cortex; LOFC: Lateral Orbitofrontal Cortex; MOFC: Medial Orbitofrontal Cortex; CN: Caudate Nucleus; NAcc: Nucleus Accumbens; NS: Not Significant; Significant difference 
highlighted in bold. Mean (Standard Deviation) are shown. Note: Data were not normally distributed according to Shapiro Wilk tests (p<.05).
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atrophy differences were observed in LOFC, ACC, CN 
or NAcc between ALS patients and controls. No correla-
tions were found between atrophy and the ACE-R and 
CBI-R.
A further exploratory analysis of the differences 
based on MOFC atrophy and relating to other prefron-
tal and striatal areas was conducted. ALS patients were 
classified based on high and low MOFC atrophy using 
median split to explore striatal differences (Median=1), 
where patients with scores of<1 were classified as low 
MOFC atrophy and patients with scores of >1 were clas-
sified as high MOFC atrophy. ALS patients with higher 
MOFC atrophy tended to have significantly higher CN 
atrophy (p<.05) and LOFC atrophy (p<.05) than those 
patients with less MOFC atrophy, with no such differ-
ences observed in NAcc and ACC (see Figure 1). There 
was no significant difference between low MOFC and 
high MOFC atrophy on the ACE-R and the CBI-R.
DISCUSSION
Our findings show significant atrophy to the medial 
portion of the OFC in ALS using visual atrophy rating 
methods applied at an individual case level. This builds 
upon previous research that showed the OFC was the 
only area where ALS patients had higher atrophy,11 
and reoccurrence of atrophy in this area in FTD when 
compared to AD.9,10 Furthermore, this area has been 
shown to have greater grey matter atrophy in patients 
with FTD and ALS-FTD.18 Our findings point to patho-
logical changes in ALS associated with specific regions 
of the OFC, which likely map onto the ALS-FTD 
subtypes.3,4 
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Figure 1. ALS patients with high and low medial orbitofrontal cortex (MOFC) atrophy comparison on striatal atrophy 
(caudate nucleus and nucleus accumbens) and prefrontal cortex atrophy (anterior cingulate cortex and lateral orbitofrontal cortex).
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Additionally, ALS patients subdivided by MOFC 
atrophy provided partial insight into prefrontal and 
striatal changes, specific to the CN and LOFC. There is 
strong striatal structural and functional connectivity 
in this region,19 with observable associated white mat-
ter changes in ALS.20 Relevantly, in FTD, frontostriatal 
atrophy profile has been observed, including the MOFC, 
CN and NAcc regions, distinguishing these patients 
from controls and also Alzheimer’s disease patients.5,21 
In terms of ALS, atrophy in the CN and OFC has been 
previously found,1,22 particularly in later stages of the 
disease.23 Additionally, reduced white matter integrity 
has been observed in ALS.24 Also, these frontostriatal 
regions have been found to be affected in ALS-FTD 
patients, with further impact on structural connectiv-
ity.25 Future research should aim to apply white mat-
ter visual atrophy rating scales (e.g.26), in parallel with 
grey matter atrophy rating, to further understanding of 
cortical and subcortical changes in ALS. As such, visu-
ally rated grey matter atrophy could be combined with 
visually rated white matter atrophy, with the possibility 
of composing a cumulative atrophy index that can be 
applied to connectivity between regions. 
Regarding the study limitations, the sample size of 
this study was small and therefore replication of this 
methodology in studies with a larger sample size would 
be of importance, so as to further determine the visu-
ally rated cortical atrophy in ALS. Further, detailed 
phenotyping (i.e. genetic status and pathology) was not 
available and additional examination in a larger sample 
with mapping of ALS-FTD variants using validated tools 
(e.g. Edinburgh Cognitive and Behavioural ALS Screen27) 
onto the gradient of atrophy observed would further 
validate the visual rating and its clinical applicability. 
Our findings do, however, emphasise the sensitivity of 
visual atrophy rating to cortical and subcortical changes, 
which can be widely used in clinical practice.
In summary, our findings reinforce the clinical value 
and research impact of visual atrophy rating of MRI 
scans, with observable frontostriatal changes (notably 
the MOFC and related CN and LOFC) detectable in ALS. 
Further research should apply this visual rating method 
to explore connectivity between cortical and subcortical 
regions, accounting for white matter changes, to allow 
comprehensive visual atrophy rating. In both clinical 
and research settings, this is an accessible method that 
can help further our understanding of neuroanatomical 
changes on the ALS-FTD spectrum, whilst supporting 
diagnosis and management.
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